Literature DB >> 6148141

Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid.

B R Nechay, S L Neldon.   

Abstract

Cisplatin and chloroplatinic acid were examined for in vitro inhibition of human renal microsomal adenosine triphosphatases activated by Na+ + K+ + Mg2+, Mg2+, and Ca2+. The concentrations of cisplatin to inhibit 50% of activity (I50) were approximately 7 X 10(-4) M for all enzymes studied; I50s of chloroplatinic acid were on the order of 10(-5) M for Na+ + K+ + Mg2+ ATPase and Ca2+ ATPase and 10(-7) M for Mg2+ ATPase in the presence of Na+ + K+ + ouabain. Inhibition of Na+ + K+ + Mg2+ ATPase by cisplatin or chloroplatinic acid was reversible and was not altered by varying Na+, K+, or Mg2+ concentrations; ATP or MgATP increased inhibition by cisplatin but not by chloroplatinic acid; acidic pH of 6.8 lowered inhibition by chloroplatinic acid but not by cisplatin. Cysteine, glutathione (-SH reagents), and ascorbic acid greatly reduced inhibition of all enzymes studied by chloroplatinic acid; in the case of cisplatin, -SH reagents had only a minimal protective effect but ascorbic acid somewhat increased inhibition. Methionine greatly increased inhibition by cisplatin but provided minimal protection in the case of chloroplatinic acid. In view of the hypothesis that inhibition of renal Na+ + K+ ATPase may be associated with tubular damage, the inhibition of Na+ + K+ ATPase may be relevant to the mechanism of platinum toxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148141

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 2.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  The effect of cisplatin on renal ATPase activity in vivo and in vitro.

Authors:  J Uozumi; C L Litterst
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.